Metagonomic sequencing has helped researchers learn more about respiratory disease pathogens because the process canprovide ...

FDA Approves Merck’s Enflonsia for RSV Prevention in Infants: Enflonsia (clesrovimab-cfor) is a long-acting monoclonal antibody approved to prevent respiratory syncytial virus (RSV) lower respiratory ...

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

Queensland’s Chief Health Officer has praised the new immunisation program that has protected hundreds of Queensland babies from Respiratory Syncytial Virus (RSV), as flu and Covid-19 cases ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrative – and likely ...

Angus Woods: Culling badgers won’t solve bovine TB – we need to address the movement of cattle in and out of farms Angus Woods with a badger cub on his Wicklow farm Angus Woods ...